Search Bar & Filters
Found 11 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the Passeo-18 Lux paclitaxel-releasing percutaneous transluminal angioplasty PTA balloon catheter for treating new or recurring cholesterol-related blockages in the arteries of the lower leg. This device has been previously studied for safety and effectiveness and is approved for use in Europe, meeting European Union safety and performance standards. The trial focuses on gathering additional information about its performance and safety in everyday medical care, especially for longer balloon lengths. All participants in this single-group trial will receive treatment with the Passeo-18 Lux drug-coated balloon, which is available in various sizes. The treatment involves using this balloon catheter during angioplasty to address lesions in the infrainguinal arteries. The study will observe how well the device delivers, inflates, deflates, and is retrieved during the procedure, and will monitor lesion restoration after treatment. Participants will be followed for up to 12 months after the procedure to assess freedom from clinically-driven target lesion revascularization and major adverse events. Additional follow-ups will continue up to 60 months to monitor outcomes like survival without amputation, quality of life changes, walking ability, and lesion patency. Various clinical assessments, questionnaires, and angiograms will be conducted during scheduled visits to evaluate safety and effectiveness over time.
Actively Recruiting
Researchers are collecting and evaluating data on various Abbott vascular medical devices used in clinical procedures. This prospective, non-randomized, open-label, multi-center registry aims to confirm the safety and performance of these devices over their expected lifetime. The study also focuses on monitoring risks, detecting new risks based on real evidence, ensuring the benefit-risk balance remains acceptable, and identifying any misuse or off-label use to verify appropriate device use. Participants receive one or more Abbott vascular devices, such as coronary and peripheral stents, pacing catheters, vascular plugs, measurement and imaging tools including FFR and OCT, peripheral and coronary dilatation catheters, guidewires, vessel closure or compression devices, and vascular access introducers. The study covers multiple device types used during vascular procedures performed as part of routine clinical care. During the study, researchers collect clinical data throughout and after the procedures, monitoring outcomes like death, myocardial infarction, target lesion revascularization, amputations, procedural complications, device success, and safety issues. Follow-up assessments occur at procedure time, 30 days, and 12 months to evaluate these outcomes. Participants are followed according to the specified schedule, which may include data collection on clinical events and device performance over time.
Actively Recruiting
This international, observational multi-centre study focuses on evaluating the safety, performance, and clinical benefit of the BeFlow Iliac Covered Stent System in patients with iliac artery stenosis or occlusion. The study aims to monitor the technical success of stent implantation, track clinical outcomes, and identify any potential unknown side effects related to the devices intended use. Participants will undergo endovascular treatment involving the permanent intraluminal placement of a covered stent in the iliac arteries to restore and improve blood flow. The study observes the devices performance over time without assigning experimental treatments, as it is an observational study involving real-world use of the stent. Throughout the study, participants will be monitored for various outcomes including the primary patency rate at 12 months, rates of stent-related complications, technical success, and changes in clinical classifications up to 60 months. Researchers will collect data on safety and effectiveness while following up for long-term results, with the study expected to conclude by the end of 2031.
Actively Recruiting
Researchers are evaluating a new medicine called NNC6019-0001 to see if it can reduce the risk of heart-related death and illness in people with transthyretin amyloid cardiomyopathy ATTR-CM, a condition that affects the heart. This phase 3 study compares NNC6019-0001 to a placebo, with participants continuing their regular heart treatments as advised by their doctors. The study aims to better understand cardiovascular outcomes in this patient group over time. Participants will receive either NNC6019-0001 or a placebo intravenously. Both groups may continue with their usual standard of care treatments as recommended by their healthcare providers. The treatment is given in a parallel design where each participant is randomly assigned to one of the two groups. The study will last up to approximately four years, allowing long-term observation of effects. During the study, participants will be regularly monitored through various assessments including questionnaires about heart health, walking tests, and measurements of heart function and biomarkers. Researchers will track cardiovascular deaths, hospital visits, and heart failure events among other outcomes. Safety and health status will be followed closely throughout the study period to evaluate the impact of the treatment compared to placebo.
Actively Recruiting
Researchers are evaluating maridebart cafraglutide as an additional treatment to standard care to reduce heart failure events, cardiovascular deaths, and improve symptoms in adults with heart failure who have preserved or mildly reduced ejection fraction and obesity. This phase 3 global trial includes a double-blind period followed by an open-label extension. The study will continue until approximately 850 primary endpoint events have occurred, focusing on serious heart failure outcomes. Participants will be randomly assigned to receive either maridebart cafraglutide or a placebo, both given by subcutaneous injection. The trial includes two parts an initial double-blind phase where neither participants nor researchers know the assigned treatment, followed by an open-label extension where all participants may receive the active drug. This design helps assess the drugs impact on heart failure and related cardiovascular events. During the study, participants will undergo regular assessments including questionnaires to measure heart failure symptoms and quality of life, blood tests for kidney function, blood sugar, cholesterol, and inflammation markers, as well as monitoring of heart failure events and mortality. The main outcome is the time until cardiovascular death or heart failure events over about 35 months. Safety and other health measures will also be tracked throughout the trial, which lasts up to about three years.
Actively Recruiting
Healthy Volunteer
This research aims to improve prediction of surgery success for patients with borderline resectable BR and locally advanced pancreatic ductal adenocarcinoma LAPDA undergoing neoadjuvant chemotherapy with FOLFIRINOX. The study focuses on combining diffusion-weighted magnetic resonance imaging DW-MRI, radiomics, and multi-omics profiling of blood samples to better identify which tumors can be surgically removed. This approach seeks to reduce unnecessary surgeries and improve treatment decisions due to challenges in current imaging and tumor marker accuracy. Participants will receive standard care including CT scans, CA 19-9 blood tests, and FOLFIRINOX chemotherapy. Additional DW-MRI scans and blood samples for genetic and molecular analysis will be collected before and after chemotherapy. If imaging shows no tumor progression and CA 19-9 levels decrease, surgical exploration may be pursued. Blood samples will also be taken during surgery and at the first follow-up visit to further evaluate tumor characteristics and treatment response. Throughout the study, participants will undergo imaging tests, blood draws, and questionnaires about health status and quality of life. Researchers will analyze data to predict surgical resectability, assess complications, and evaluate disease-free and overall survival over several years. This comprehensive monitoring aims to enhance personalized treatment plans while minimizing risks from unnecessary procedures.
Actively Recruiting
Researchers are evaluating a digital tool integrated into electronic health records to collect both clinical and patient-reported outcomes in men diagnosed with localized or locally advanced prostate cancer. The study aims to improve the quality of care by systematically capturing these outcomes over a long period. This observational study is led by Universitaire Ziekenhuizen KU Leuven and focuses on men aged 18 and older diagnosed with prostate cancer confined to or locally extending beyond the prostate gland without distant metastases. Participants will receive standard care for prostate cancer as determined by their treating physician. No additional medications or procedures are provided through the study. Clinical data will be recorded using predefined electronic forms within the health record system, while patient-reported outcomes will be collected electronically. Treatment decisions remain at the discretion of the physician, and no experimental interventions are involved. During the study, participants will be followed for up to 10 years after diagnosis. Researchers will assess the reporting of clinical parameters and patient-reported outcomes at various time points, including quality of life at diagnosis, 6 months, 1 year, and annually thereafter. They will also monitor disease recurrence, progression, overall survival, and prostate cancer-specific mortality. This long-term follow-up aims to support better understanding and management of prostate cancer outcomes.
Actively Recruiting
Researchers are evaluating the safety and clinical performance of the Oscar Peripheral Multifunctional Catheter in patients with peripheral arterial disease affecting the femoral, popliteal, and infrapopliteal arteries. This prospective, multicenter, observational study aims to confirm procedural success and monitor in-hospital complications such as vessel perforation, rupture, acute occlusion, and distal embolization. The study includes patients with significant artery narrowing and specific lesion characteristics, who require endovascular intervention. The study uses the Oscar Peripheral Multifunctional Catheter, which includes three components the Oscar Support Catheter with integrated Lock Grip, the Oscar Dilator, and the Oscar PTA Balloon. The device is used to dilate lesions in the target arteries. The study focuses on procedural outcomes such as successful crossing of the target lesion, residual stenosis after vessel preparation, and absence of procedural complications. Treatments of inflow lesions may be performed before the target lesion treatment according to local standards. Participants will undergo the index procedure where procedural success and complications are closely monitored. Assessments include measuring procedural success rates, rates of adverse device effects, distal embolization, vessel rupture, perforation, and acute occlusion, as well as flow-limiting dissections and amputation occurrences within 30 days. Data on residual stenosis and crossing success will be collected. The study period extends until January 2026, with follow-up evaluations up to 30 days after discharge.
Actively Recruiting
Researchers are collecting detailed data about suicide attempts and suicidal thoughts among people who come to healthcare services in Flanders. The study aims to understand how often these behaviors occur, the methods used, and how many receive proper follow-up care after a suicide attempt. This observational study uses a structured interview tool called the Guideline for Suicide Care and Evaluation LOES to gather comprehensive information. Participants undergo a two-part semi-structured interview administered by trained nurses, psychologists, or psychiatrists. The first part happens soon after admission to a healthcare facility and collects information on emotional state, mental health history, social support, hopelessness, and suicidal behavior. The second part provides a deeper evaluation of risk factors, treatment needs, motivations, planning, and coping strategies related to suicidality. Throughout the study, participants provide demographic, clinical, and psychological information through interviews. Researchers assess suicidal intent, planning, past behavior, substance use risk, and care needs. The study tracks treatment agreements and care pathways after assessment. Data collection occurs at the initial presentation, with no drug or medical treatment being tested. The total participation time varies depending on the individuals healthcare encounters and follow-up.
Actively Recruiting
Researchers are evaluating the effects of nucresiran compared to placebo in patients with transthyretin amyloidosis with cardiomyopathy, a condition involving abnormal protein buildup in the heart. This study aims to assess whether nucresiran can reduce deaths from any cause and cardiovascular events, and also improve patient-reported health status and quality of life. The trial is a Phase 3, randomized, double-blind study focused on treatment outcomes. Participants will be randomly assigned to receive either nucresiran 300 mg or a placebo, both given as subcutaneous injections every six months during the double-blind period lasting up to 32 months with a maximum of 5 years. After this period, all participants enter an open-label extension where everyone receives nucresiran 300 mg every six months. Patients may continue some background therapies as decided by their investigators. Throughout the study, participants will be monitored for mortality and cardiovascular events, including hospitalizations and urgent heart failure visits. Health status and quality of life will be assessed using questionnaires. Safety and efficacy are evaluated through regular assessments during the double-blind phase and ongoing follow-up during the extension. The total study duration extends up to approximately 7 years, including follow-up after the main treatment period.
1-10 of 11
1